{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T12:57:08Z","timestamp":1780059428392,"version":"3.54.0"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,3,31]],"date-time":"2009-03-31T00:00:00Z","timestamp":1238457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,3,31]],"date-time":"2009-03-31T00:00:00Z","timestamp":1238457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Skin Pharmacol"],"abstract":"<jats:p>Porphyria cutanea tarda (PCX) is characterized by cutaneous symptoms in association with hepatic accumulation and urinary excretion of mainly uro- and heptacarboxyporphyrins. 24 PCX patients excreting urinary porphyrins between 1.9 and 5.8 \u00b5mol\/24 h (normal &lt; 0.2) were treated with chloroquine at a dose of 125 mg twice a week. During the first phase of therapy urinary porphyrin excretion transiently increased 1.1- to 2.9-fold indicating a phase of mobilization. A slight initial elevation was also found regarding the activities of serum amino-transferases reflecting the hepatotoxic effect of chloroquine. Xhe clinical symptoms disappeared after a period ranging from 2 to 6 months, and after an average of 12 months the porphyrin excretion in all patients had returned to nearly normal values.<\/jats:p>","DOI":"10.1159\/000211340","type":"journal-article","created":{"date-parts":[[2009,4,2]],"date-time":"2009-04-02T10:14:27Z","timestamp":1238667267000},"page":"156-161","source":"Crossref","is-referenced-by-count":21,"title":["Treatment of Porphyria cutanea tarda by the Effect of Chloroquine on the Liver"],"prefix":"10.1159","author":[{"given":"Anne","family":"Freesemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margareta","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Sieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred O.","family":"Doss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2009,3,31]]},"container-title":["Skin Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/211340","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000211340","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T22:40:38Z","timestamp":1777761638000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000211340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,31]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000211340","archive":["Portico"],"relation":{},"ISSN":["1011-0283","2571-7162"],"issn-type":[{"value":"1011-0283","type":"print"},{"value":"2571-7162","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,31]]}}}